World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
86
Citations
27582
World Ranking
1263
National Ranking
660

David W. Vaughn publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where David W. Vaughn sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 189 publications — 30th percentile

30% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

David W. Vaughn D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where David W. Vaughn sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 86 D-Index — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

David W. Vaughn is affiliated with the Bill & Melinda Gates Foundation in the United States. Their research primarily focuses on medicine, with a concentration on infectious diseases and public health. The scientist's work encompasses multiple intersecting subfields including Epidemiology, Immunology, and Environmental and Occupational Health.

Their research covers several significant topics, among which are:

  • SARS-CoV-2 and COVID-19 Research
  • Mosquito-borne diseases and control
  • Malaria Research and Control
  • Respiratory viral infections research
  • Vaccine Coverage and Hesitancy
  • Viral gastroenteritis research and epidemiology
  • Viral Infections and Vectors

David W. Vaughn has authored and contributed to various scientific papers. Notable recent publications include:

  • Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization, 2021, Vaccine
  • Scientific rationale for developing potent RBD-based vaccines targeting COVID-19, 2021, npj Vaccines
  • Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities-workshop report, 2023, npj Vaccines
  • Route of inoculation and mosquito vector exposure modulate dengue virus replication kinetics and immune responses in rhesus macaques, 2020, PLoS Neglected Tropical Diseases
  • Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study, 2020, American Journal of Tropical Medicine and Hygiene

The scientist frequently publishes in a set of key venues, including:

  • American Journal of Tropical Medicine and Hygiene
  • npj Vaccines
  • Vaccine
  • PLoS Neglected Tropical Diseases
  • The Lancet Global Health

Throughout their work, David W. Vaughn collaborates with several coauthors, notably:

  • Stephen J. Thomas
  • Richard G. Jarman
  • Peter G. Smith
  • Padmini Srikantiah
  • Heather Friberg

Best Publications

  • Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease Severity

    David W. Vaughn;Sharone Green;Siripen Kalayanarooj;Bruce L. Innis

  • High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever

    Daniel H. Libraty;Paul R. Young;Darren Pickering;Timothy P. Endy

  • Early Clinical and Laboratory Indicators of Acute Dengue Illness

    S. Kalayanarooj;D. W. Vaughn;S. Nimmannitya;S. Green

  • Dengue Virus Structural Differences That Correlate with Pathogenesis

    Katrin C. Leitmeyer;David W. Vaughn;Douglas M. Watts;Rosalba Salas

  • Neurological manifestations of dengue infection.

    Tom Solomon;Nguyen Minh Dung;David W Vaughn;Rachel Kneen;Rachel Kneen

  • Safety and Efficacy of a Recombinant Hepatitis E Vaccine

    Mrigendra Prasad Shrestha;Robert McNair Scott;Durga Man Joshi;Mammen P. Mammen

  • Differing Influences of Virus Burden and Immune Activation on Disease Severity in Secondary Dengue-3 Virus Infections

    Daniel H. Libraty;Timothy P. Endy;Huo-Shu H. Houng;Sharone Green

  • Epidemiology of Inapparent and Symptomatic Acute Dengue Virus Infection: A Prospective Study of Primary School Children in Kamphaeng Phet, Thailand

    Timothy P. Endy;Supamit Chunsuttiwat;Ananda Nisalak;Daniel H. Libraty

  • Dengue in the early febrile phase : Viremia and antibody responses

    David W. Vaughn;Sharone Green;Siripen Kalayanarooj;Bruce L. Innis

  • SEROTYPE-SPECIFIC DENGUE VIRUS CIRCULATION AND DENGUE DISEASE IN BANGKOK, THAILAND FROM 1973 TO 1999

    Ananda Nisalak;Timothy P. Endy;Suchitra Nimmannitya;Siripen Kalayanarooj

  • Early Immune Activation in Acute Dengue Illness Is Related to Development of Plasma Leakage and Disease Severity

    Sharone Green;David W. Vaughn;Siripen Kalayanarooj;Suchitra Nimmannitya

  • Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

    Anna P. Durbin;Ruth A. Karron;Wellington Sun;David W. Vaughn

  • Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

    Nathalie Garçon;David W Vaughn;Arnaud M Didierlaurent

  • Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.

    Timothy P. Endy;Ananda Nisalak;Supamit Chunsuttitwat;David W. Vaughn

  • Poliomyelitis-like illness due to Japanese encephalitis virus.

    Tom Solomon;Rachel Kneen;Nguyen Minh Dung;Vo Cong Khanh

  • Dengue Hemorrhagic Fever in Infants: Research Opportunities Ignored

    Scott B. Halstead;Nguyen Trong Lan;Thein Thein Myint;Than Nu Shwe

  • Analysis of Repeat Hospital Admissions for Dengue to Estimate the Frequency of Third or Fourth Dengue Infections Resulting in Admissions and Dengue Hemorrhagic Fever, and Serotype Sequences

    Robert V. Gibbons;Siripen Kalanarooj;Richard G. Jarman;Ananda Nisalak

  • Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers

    N. Kanesa-thasan;W. Sun;G. Kim-Ahn;S. Van Albert

  • HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais

    H. A. F. Stephens;H. A. F. Stephens;R. Klaythong;M. Sirikong;D. W. Vaughn

  • Etiology of interepidemic periods of mosquito-borne disease

    S I Hay;M F Myers;D S Burke;D W Vaughn

  • Impact of Dengue Virus Infection on Feeding Behavior of Aedes aegypti

    Kenneth B. Platt;Kenneth J. Linthicum;Khin S. A. Myint;Bruce L. Innis

  • Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever.

    Sharone Green;Sathit Pichyangkul;David W. Vaughn;Siripen Kalayanarooj

  • Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis

    Tom Solomon;Nguyen Minh Dung;Rachel Kneen;Le Thi Thu Thao

  • Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance.

    Stephen J. Thomas;Ananda Nisalak;Kathryn B. Anderson;Daniel H. Libraty

  • Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study.

    Katie B Anderson;Supamit Chunsuttiwat;Ananda Nisalak;Mammen P Mammen

  • Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial

    Tom Solomon;Tom Solomon;Nguyen Minh Dung;Bridget Wills;Rachel Kneen

  • Viremia, Fecal Shedding, and IgM and IgG Responses in Patients with Hepatitis E

    Edward T. Clayson;Khin Saw Aye Myint;Rapin Snitbhan;David W. Vaughn

  • Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.

    Robert Edelman;Steven S. Wasserman;Sacared A. Bodison;Robert J. Putnak

  • Extinction and rapid emergence of strains of dengue 3 virus during an interepidemic period.

    V. Wittke;T.E. Robb;H.M. Thu;A. Nisalak

  • Pathogenesis and Clinical Features of Japanese Encephalitis and West Nile Virus Infections

    T. Solomon;D. W. Vaughn

Frequent Co-Authors

Bruce L. Innis
Bruce L. Innis GlaxoSmithKline (United Kingdom)
Ananda Nisalak
Ananda Nisalak United States Department of the Army
Sharone Green
Sharone Green University of Massachusetts Chan Medical School
Francis A. Ennis
Francis A. Ennis University of Massachusetts Chan Medical School
Alan L. Rothman
Alan L. Rothman University of Rhode Island
Timothy P. Endy
Timothy P. Endy SUNY Upstate Medical University
Charles H. Hoke
Charles H. Hoke Walter Reed Army Institute of Research
Kenneth H. Eckels
Kenneth H. Eckels Walter Reed Army Institute of Research
Daniel H. Libraty
Daniel H. Libraty University of Massachusetts Chan Medical School
Ichiro Kurane
Ichiro Kurane National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Immunology in the USA often goes hand-in-hand with expanding knowledge in healthcare fields like nursing. For those interested in advanced clinical roles, understanding the doctor of nursing practice salary can provide insight into the financial benefits of higher education and specialized training.

Many nurses seek to advance their expertise through focused programs such as the fnp to acute care np bridge program, which helps Family Nurse Practitioners transition to more specialized acute care roles. This pathway is ideal for those aiming to work in critical care settings, closely complementing immunology knowledge.

For students pursuing expedited education, the market offers excellent options like the accelerated nurse practitioner program. These programs allow faster progression to licensure and specialized practice, perfect for professionals eager to enhance their clinical skills efficiently.

Additionally, individuals without a nursing background can access foundational education through the best online rn programs for non nurses. These programs open the door to nursing careers, providing a solid base in healthcare that complements immunology studies and future clinical roles.

Best Scientists Citing David W. Vaughn

Trending Scientists